ロード中...
Targeted treatments for multiple myeloma: specific role of carfilzomib
Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Ph...
保存先:
| 出版年: | Pharmgenomics Pers Med |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4325627/ https://ncbi.nlm.nih.gov/pubmed/25691814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S39085 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|